Mutual of America Capital Management LLC Has $2.84 Million Holdings in Hologic, Inc. (NASDAQ:HOLX)

Mutual of America Capital Management LLC cut its stake in Hologic, Inc. (NASDAQ:HOLX) by 4.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 38,297 shares of the medical equipment provider’s stock after selling 1,989 shares during the period. Mutual of America Capital Management LLC’s holdings in Hologic were worth $2,844,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in HOLX. Innealta Capital LLC acquired a new position in shares of Hologic during the 2nd quarter worth about $25,000. iA Global Asset Management Inc. acquired a new position in shares of Hologic during the 1st quarter worth about $37,000. Cranbrook Wealth Management LLC acquired a new position in shares of Hologic during the 2nd quarter worth about $47,000. Mather Group LLC. acquired a new position in shares of Hologic during the 1st quarter worth about $48,000. Finally, Massmutual Trust Co. FSB ADV boosted its stake in shares of Hologic by 24.7% during the 1st quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock worth $54,000 after buying an additional 137 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently commented on HOLX. JPMorgan Chase & Co. increased their price objective on shares of Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 30th. Needham & Company LLC reiterated a “buy” rating and issued a $90.00 target price on shares of Hologic in a research note on Tuesday, September 17th. Evercore ISI raised their target price on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research note on Tuesday, July 30th. StockNews.com downgraded shares of Hologic from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, September 18th. Finally, Stephens reiterated an “overweight” rating and issued a $92.00 target price on shares of Hologic in a research note on Tuesday, July 30th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, Hologic has a consensus rating of “Moderate Buy” and a consensus price target of $87.60.

Hologic Stock Down 0.3 %

Hologic stock opened at $81.21 on Wednesday. The stock has a market cap of $18.95 billion, a P/E ratio of 41.43, a P/E/G ratio of 2.53 and a beta of 0.98. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. Hologic, Inc. has a twelve month low of $64.02 and a twelve month high of $84.67. The company’s 50-day moving average price is $80.96 and its two-hundred day moving average price is $77.20.

Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, topping the consensus estimate of $1.02 by $0.04. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1 billion. During the same period last year, the firm earned $0.93 earnings per share. The business’s revenue for the quarter was up 2.7% on a year-over-year basis. As a group, analysts expect that Hologic, Inc. will post 4.09 EPS for the current year.

Insider Buying and Selling

In related news, CEO Stephen P. Macmillan sold 3,672 shares of the stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total transaction of $294,237.36. Following the sale, the chief executive officer now owns 1,157,562 shares in the company, valued at approximately $92,755,443.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Hologic news, insider Benjamin Jordan Cohn sold 5,093 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $81.99, for a total value of $417,575.07. Following the sale, the insider now owns 10,476 shares in the company, valued at $858,927.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Stephen P. Macmillan sold 3,672 shares of Hologic stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total transaction of $294,237.36. Following the transaction, the chief executive officer now owns 1,157,562 shares in the company, valued at approximately $92,755,443.06. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,280 shares of company stock worth $1,469,973. Corporate insiders own 1.75% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.